Knowledge of these mechanisms would provide a framework for the development of new therapeutic agents capable of manipulating BRCA1 splicing and treating BRCA1-related cancers (eg. breast ovarian and prostate cancer). This evidence concerns the gene BRCA1 and prostate cancer.